Nexletol Patent Expiration

Nexletol is a drug owned by Esperion Therapeutics Inc. It is protected by 10 US drug patents filed from 2020 to 2024. Out of these, 5 drug patents are active and 5 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 19, 2040. Details of Nexletol's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7335799 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(1 year, 4 months from now)

Active
US11613511 Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

Active
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9624152 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months ago)

Expired
US10118881 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months ago)

Expired
US10941095 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months ago)

Expired
US9000041 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months ago)

Expired
US8497301 Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(6 months ago)

Expired
US11744816 Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

Active
US11926584 Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

Active
US11760714 Methods of making bempedoic acid and compositions of the same
Jun, 2040

(15 years from now)

Active


FDA has granted several exclusivities to Nexletol. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Nexletol, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Nexletol.

Exclusivity Information

Nexletol holds 3 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Nexletol's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Indication(I-943) Mar 22, 2027
New Indication(I-944) Mar 22, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Nexletol is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nexletol's family patents as well as insights into ongoing legal events on those patents.

Nexletol's family patents

Nexletol has patent protection in a total of 17 countries. It's US patent count contributes only to 47.1% of its total global patent coverage. Click below to unlock the full patent family tree for Nexletol.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Nexletol's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 19, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Nexletol Generics:

There are no approved generic versions for Nexletol as of now.





About Nexletol

Nexletol is a drug owned by Esperion Therapeutics Inc. It is used for lowering LDL-C in patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Nexletol uses Bempedoic Acid as an active ingredient. Nexletol was launched by Esperion Theraps Inc in 2020.

Market Authorisation Date:

Nexletol was approved by FDA for market use on 21 February, 2020.

NCE-1 date:

NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Nexletol is 21 February, 2020, its NCE-1 date is estimated to be 22 February, 2024

Active Ingredient:

Nexletol uses Bempedoic Acid as the active ingredient. Check out other Drugs and Companies using Bempedoic Acid ingredient

Treatment:

Nexletol is used for lowering LDL-C in patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease.

Dosage:

Nexletol is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
180MG TABLET Prescription ORAL